Company news
TG Therapeutics, Inc. news in 2023
TG Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
TG Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference
November 26, 2023
TG Therapeutics to Participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) Conference
November 2, 2023
TG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
October 31, 2023
TG Therapeutics to Host Conference Call on Third Quarter 2023 Financial Results and Business Update
October 29, 2023
TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
October 11, 2023
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
October 1, 2023
TG Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
September 21, 2023
TG Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 6, 2023
TG Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
July 31, 2023
TG Therapeutics and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI® (ublituximab-xiiy)
July 31, 2023
TG Therapeutics to Host Conference Call on Second Quarter 2023 Financial Results and Business Update
July 30, 2023
TG Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
June 4, 2023
TG Therapeutics Announces European Commission Approval for BRIUMVI® (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults
May 31, 2023
TG Therapeutics Announces Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting
May 30, 2023
TG Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference
May 3, 2023
TG Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
April 30, 2023
TG Therapeutics to Host Conference Call on First Quarter 2023 Financial Results and Business Update
April 27, 2023
TG Therapeutics Announces Issuance of Permanent J-Code for BRIUMVI® (ublituximab-xiiy) from Centers for Medicare and Medicaid Services
April 26, 2023
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 75th Annual Meeting
April 24, 2023
TG Therapeutics Announces Positive CHMP Opinion for BRIUMVI™ (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults
March 30, 2023
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the American Academy of Neurology 75th Annual Meeting
March 2, 2023
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results
February 27, 2023
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2022 Financial Results and Business Update
February 23, 2023
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
February 23, 2023
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab) in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
February 13, 2023
TG Therapeutics Announces Commercial Launch of BRIUMVI™ (ublituximab-xiiy) for the Treatment of Adult Patients with Relapsing Forms of Multiple Sclerosis
January 25, 2023
TG Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 5, 2023